nach oben

Erschienen in:

01.04.2014 | Original Paper

Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics

verfasst von: Jun Liang, Xianli Zhang, Shao Xie, Xiuping Zhou, Qiong Shi, Jinxia Hu, Weifeng Wang, Weifeng Qi, Rutong Yu

Erschienen in: Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Ubiquitin-specific protease 22 (USP22) exhibits an important function in tumor progression and oncogenesis. The aim of this study was to investigate the role of USP22 and the association with its potential targets in patients with glioma. To our knowledge, this is the first study that determines the relationship between USP22 expression and clinicopathological significance in glioma. In our study, USP22 protein levels were detected by Western blot analysis. The protein levels of USP22 in glioma tissues were significantly higher than non-tumors. The immunohistochemistry results showed that USP22 protein was overexpressed in glioma tissues compared with non-tumors. The higher the grade of gliomas, the higher the level of USP22 expression. Further, the results of Kaplan–Meier analysis indicated that patients with high USP22 expression had significantly worse overall survival than patients with low expression of USP22. It suggested that USP22 overexpression may be associated with poor prognosis in patients with glioma. It may represent a novel prognostic biomarker or a target for improving the treatment efficiency of patients with glioma.

Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet. 2003;361(9354):323–31.PubMedCrossRef

Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.PubMedCrossRef

Buckner JC, Brown PD, O’Neill BP, et al. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271–86.PubMedCrossRef

Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479–89.PubMed

Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2001;2(2):120–9.PubMedCrossRef

Donato V, Monaco A, Rollo A, et al. Elderly and poor prognosis patients with high grade glioma: hypofractionated radiotherapy. Clin Ter. 2007;158(3):227–30.PubMed

Rampling R, James A, Papanastassiou V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 2):ii24–30.PubMedCentralPubMed

Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458(7237):438–44.PubMedCrossRef

Lee HJ, Kim MS, Shin JM, et al. The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 2006;6(3):277–84.PubMedCrossRef

10.

Zhang XY, Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008;29(1):102–11.PubMedCentralPubMedCrossRef

11.

Zhang XY, Pfeiffer HK, Thorne AW, et al. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 2008;7(11):1522–4.PubMedCentralPubMedCrossRef

12.

Bouchard C, Dittrich O, Kiermaier A, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001;15(16):2042–7.PubMedCentralPubMedCrossRef

13.

Liu YL, Yang YM, Xu H, et al. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol. 2011;103(3):283–9.PubMedCrossRef

14.

Liu YL, Yang YM, Xu H, et al. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010;25(11):1800–5.PubMedCrossRef

15.

Zhang Y, Yao L, Zhang X, Ji H, et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 2011;137(8):1245–53.PubMedCrossRef

16.

Lv L, Xiao XY, Gu ZH, et al. Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 2011;346(1–2):11–21.PubMedCrossRef

17.

Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011;12(9):924–30.PubMedCentralPubMedCrossRef

18.

Chipumuro E, Henriksen MA. The ubiquitin hydrolase USP22 contributes to 3′-end processing of JAK-STAT-inducible genes. FASEB J. 2012;26(2):842–54.PubMedCrossRef

19.

Liu YL, Jiang SX, Yang YM, et al. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 2012;62(1):229–35.PubMedCrossRef

20.

Zhao Y, Lang G, Ito S, et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 2008;29(1):92–101.PubMedCrossRef

21.

Yang M, Liu YD, Wang YY, et al. Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol. 2014;35(2):929–934.

22.

Ling SB, Sun DG, Tang B, et al. Knock-down of USP22 by small interfering RNA interference inhibits HepG2 cell proliferation and induces cell cycle arrest. Cell Mol Biol (Noisy-le-grand). 2012;58(Suppl):OL1803–8.

23.

Xu H, Liu YL, Yang YM, et al. Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis. 2012;27(1):21–30.PubMedCrossRef

24.

Li ZH, Yu Y, Du C, et al. RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol Lett. 2013;5(4):1290–4.PubMedCentralPubMed

25.

Yang DD, Cui BB, Sun LY, et al. The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys. 2011;61(3):703–10.PubMedCrossRef

26.

Vlachostergios PJ, Papandreou CN. The Bmi-1/NF-kappaB/VEGF story: another hint for proteasome involvement in glioma angiogenesis? J Cell Commun Signal. 2013;7(4):235–7.PubMedCentralPubMedCrossRef

27.

Li Y, Hu J, Guan F, et al. Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1. Oncol Rep. 2013;29(5):1805–10.PubMed

28.

Jiang L, Song L, Wu J, et al. Bmi-1 promotes glioma angiogenesis by activating NF-kappaB signaling. PLoS One. 2013;8(1):e55527.PubMedCentralPubMedCrossRef

29.

Hu J, Liu YL, Piao SL, et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer. 2012;77(3):593–9.PubMedCrossRef

30.

Liu Y, Yang Y, Xu H, et al. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol. 2010;19(4):194–200.PubMedCrossRef

Titel: Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics
verfasst von: Jun Liang
Xianli Zhang
Shao Xie
Xiuping Zhou
Qiong Shi
Jinxia Hu
Weifeng Wang
Weifeng Qi
Rutong Yu
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 4/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0899-2

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection

Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer

LRRC4 haplotypes are associated with pituitary adenoma in a Chinese population

Association between polymorphisms at promoters of XRCC5 and XRCC6 genes and risk of breast cancer

Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma

Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie